UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205 / Bismuth-206

Cancer biology & therapy, 2008-10, Vol.7 (10), p.1547-1554

2008

Volltextzugriff (PDF)

Targeted alpha therapy approach to the management of pancreatic cancer

Cancers, 2011-04, Vol.3 (2), p.1821-1843

2011

Volltextzugriff (PDF)

Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model

Cancer biology & therapy, 2006-04, Vol.5 (4), p.386-393

2006

Volltextzugriff (PDF)

In vivo studies of pharmacokinetics and efficacy of bismuth-213 labeled antimelanoma monoclonal antibody 9.2.27

Cancer biology & therapy, 2005-07, Vol.4 (7), p.763-768

2005

Volltextzugriff (PDF)

Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma

Immunotherapy, 2011-09, Vol.3 (9), p.1041-1050

2011

Volltextzugriff (PDF)

Inhibition of Micrometastatic Prostate Cancer Cell Spread in Animal Models By 213Bilabeled Multiple Targeted α Radioimmunoconjugates

Clinical cancer research, 2009-02, Vol.15 (3), p.865-875

2009

Volltextzugriff (PDF)

Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma

Cancer biology & therapy, 2007-06, Vol.6 (6), p.846-852

2007

Volltextzugriff (PDF)

In vitro targeting of NG2 antigen by 213Bi-9.2.27 α-immunoconjugate induces cytotoxicity in human uveal melanoma cells

Investigative ophthalmology & visual science, 2005-12, Vol.46 (12), p.4365-4371

2005

Volltextzugriff (PDF)

Cytotoxicity of breast cancer cells overexpressing HER2/neu by 213Bi-Herceptin radioimmunoconjugate

Cancer letters, 2005-02, Vol.218 (2), p.181-190

2005

Volltextzugriff (PDF)

Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted α radioimmunoconjugates

The Prostate, 2006-12, Vol.66 (16), p.1753-1767

2006

Volltextzugriff (PDF)

In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopes

Leukemia research, 2002, Vol.26 (1), p.37-43

2002

Volltextzugriff (PDF)

Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted α-therapy with 213Bi-conjugates

International journal of radiation oncology, biology, physics, 2004-11, Vol.60 (3), p.896-908

2004

Volltextzugriff (PDF)

Analysis of patient survival in a Phase I trial of systemic targeted [alpha]-therapy for metastatic melanoma

Immunotherapy, 2011-09, Vol.3 (9), p.1041

2011

Volltextzugriff (PDF)

Analysis of patient survival in a Phase I trial of systemic targeted αα-therapy for metastatic melanoma

Immunotherapy, 2011-09, Vol.3 (9), p.1041-1050

2011

Volltextzugriff (PDF)

Analysis of patient survival in a Phase I trial of systemic targeted alpha alpha -therapy for metastatic melanoma

Immunotherapy, 2011-09, Vol.3 (9), p.1041-1050

2011

Volltextzugriff (PDF)

Control of prostate cancer spheroid growth using 213 Bi-labeled multiple targeted α radioimmunoconjugates: Targeted Alpha Therapy for Human Prostate Cancer

The Prostate, 2006-12, Vol.66 (16), p.1753-1767

2006

Volltextzugriff (PDF)

Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin α-conjugate

Cancer letters, 2004-03, Vol.205 (2), p.161-171

2004

Volltextzugriff (PDF)

Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin [alpha]-conjugate

Cancer letters, 2004-03, Vol.205 (2), p.161

2004

Volltextzugriff (PDF)

Pharmacokinetics and toxicity of (213)Bi-labeled PAI2 in preclinical targeted alpha therapy for cancer

Cancer biology & therapy, 2007-06, Vol.6 (6), p.898

2007

Volltextzugriff (PDF)

Targeted alpha therapy of cancer: In vitro and preclinical studies leading to a phase 1 clinical trial

Rizvi, Syed M. Abbas

2003

Volltextzugriff (PDF)

In Vitro Targeting of NG2 Antigen by 213 Bi-9.2.27 α-Immunoconjugate Induces Cytotoxicity in Human Uveal Melanoma Cells

Investigative ophthalmology & visual science, 2005-12, Vol.46 (12), p.4365

2005

Volltextzugriff (PDF)

In Vitro Targeting of NG2 Antigen by 213Bi-9.2.27 {alpha}-Immunoconjugate Induces Cytotoxicity in Human Uveal Melanoma Cells

Investigative ophthalmology & visual science, 2005-12, Vol.46 (12), p.4365

2005

Volltextzugriff (PDF)

An advanced Wigner–Ville time–frequency analysis of Lamb wave signals based upon an autoregressive model for efficient damage inspection

Measurement science & technology, 2021-09, Vol.32 (9), p.95601

2021

Volltextzugriff (PDF)

Lamb wave damage severity estimation using ensemble-based machine learning method with separate model network

Smart materials and structures, 2021-11, Vol.30 (11), p.115016

2021

Volltextzugriff (PDF)

Green finance and renewable energy: A worldwide evidence

Energy economics, 2023-02, Vol.118, p.106499, Article 106499

2023

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(36)

Publikationsform

Sprache

Englisch
(42)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Humans
(16)
Life Sciences & Biomedicine
(11)
Male
(10)
Technology
(7)
Antibodies, Monoclonal - Therapeutic Use
(6)
Biological And Medical Sciences
(6)
Biology
(6)
Cancer
(6)
Engineering
(6)
Female
(6)
Medical Sciences
(6)
Middle Aged
(6)
Cell Line, Tumor
(5)
Immunoconjugates - Therapeutic Use
(5)
Neoplasm Metastasis
(5)
Oncology
(5)
Proteins
(5)
Radioisotopes - Therapeutic Use
(5)
Targeted Alpha Therapy
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205 / Bismuth-206

Targeted alpha therapy approach to the management of pancreatic cancer

Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model

In vivo studies of pharmacokinetics and efficacy of bismuth-213 labeled antimelanoma monoclonal antibody 9.2.27

Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma

Inhibition of Micrometastatic Prostate Cancer Cell Spread in Animal Models By 213Bilabeled Multiple Targeted α Radioimmunoconjugates

Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma

In vitro targeting of NG2 antigen by 213Bi-9.2.27 α-immunoconjugate induces cytotoxicity in human uveal melanoma cells

Cytotoxicity of breast cancer cells overexpressing HER2/neu by 213Bi-Herceptin radioimmunoconjugate

Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted α radioimmunoconjugates

In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopes

Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted α-therapy with 213Bi-conjugates

Analysis of patient survival in a Phase I trial of systemic targeted [alpha]-therapy for metastatic melanoma

Analysis of patient survival in a Phase I trial of systemic targeted αα-therapy for metastatic melanoma

Analysis of patient survival in a Phase I trial of systemic targeted alpha alpha -therapy for metastatic melanoma

Control of prostate cancer spheroid growth using 213 Bi-labeled multiple targeted α radioimmunoconjugates: Targeted Alpha Therapy for Human Prostate Cancer

Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin α-conjugate

Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin [alpha]-conjugate

Pharmacokinetics and toxicity of (213)Bi-labeled PAI2 in preclinical targeted alpha therapy for cancer

Targeted alpha therapy of cancer: In vitro and preclinical studies leading to a phase 1 clinical trial

In Vitro Targeting of NG2 Antigen by 213 Bi-9.2.27 α-Immunoconjugate Induces Cytotoxicity in Human Uveal Melanoma Cells

In Vitro Targeting of NG2 Antigen by 213Bi-9.2.27 {alpha}-Immunoconjugate Induces Cytotoxicity in Human Uveal Melanoma Cells

An advanced Wigner–Ville time–frequency analysis of Lamb wave signals based upon an autoregressive model for efficient damage inspection

Lamb wave damage severity estimation using ensemble-based machine learning method with separate model network

Green finance and renewable energy: A worldwide evidence

Suchergebnisse filtern